Affiliation:
1. Oncology Research Institute, Tomsk National Medical Research Center of the Russian Academy of Sciences;
National Tomsk State Research University
2. Oncology Research Institute, Tomsk National Medical Research Center of the Russian Academy of Sciences
Abstract
It is known that currently PARP inhibitors are actively used in the treatment of tumors of the female reproductive system. A large number of studies have been presented demonstrating the effectiveness of PARP inhibitors in the treatment of BRCA-associated ovarian cancer. It was found that mutations in the BRCA1 and BRCA2 genes are also characteristic of breast cancer (BC). However, PARP inhibitors are rarely used in clinical practice in the treatment of BC. So far, only olaparib has become the first PARP inhibitor approved for the treatment of metastatic BC. This review presents data over the past ten years showing the high efficiency of PARP inhibitors in the treatment of malignant neoplasms of the mammary gland. In 7 of 28 studies analyzed, positive results were achieved with combined treatment with chemotherapeutic drugs and PARP inhibitors. So, for example, in two studies in the treatment of BRCA-associated BC, the response to treatment in patients was 72.5–73.2 %. Thus, PARP inhibitors are of great interest and are of practical value in the treatment of patients with BC.
Publisher
Publishing House ABV Press
Subject
Pharmacology (medical),Obstetrics and Gynecology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery
Reference49 articles.
1. De Murcia J.M., Ricoul M., Tartier L. et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003;22(9):2255–63. DOI: 10.1093/emboj/cdg206.
2. Citarelli M., Teotia S., Lamb R.S. Evolutionary history of the poly-(ADP-ribose) polymerase gene family in eukaryotes. BMC Evol Biol 2010;10(1):308. DOI: 10.1186/1471-2148-10-308
3. Hassa P.O., Haenni S.S., Elser M. et al. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol Mol Biol Rev 2006;70(3):789–829. DOI: 10.1128/MMBR.00040-05.
4. Piskunova T.S., Yurova M.N., Zabezhinski M.A. et al. Poly-(ADP-ribosa)-polymerase – the relationships with life span and carcinogenesis. Uspekhi gerontologii = Advances in Gerontology 2007;20(2):82–90. (In Russ.).
5. Efremova A.S., Shram S.I., Myasoedov N.F., Doxorubicin causes transient activattion of protein poly-ADF-ribosylation in H9c2 cardiomyocytes. Doklady Akademii nauk = Reports of the Academy of Sciences 2015;464(6):745–9. (In Russ.). DOI: 10.7868/S0869565215300246.